We Work for Health Virginia

01/30/2026

Virginia’s life sciences momentum is real and worth protecting. As the General Assembly considers SB 278, this thoughtful analysis from John Newby with Virginia Biotechnology Association makes a compelling case that expanding the 340B program as-is could raise costs for patients, employers, and taxpayers while undermining Virginia’s biotech competitiveness. Smart health policy should lower costs without driving innovation out of the Commonwealth.

Virginia lawmakers should protect patients and the commonwealth’s positive biotechnology industry momentum by rejecting SB 278 and pursuing policies that meaningfully lower health care costs without driving innovation out of the commonwealth.

01/20/2026

CMS recently announced new healthcare transparency rules, a positive step toward tackling the anti-competitive practices of corporate insurers and their subsidiary PBMs.

WASHINGTON, D.C. (Dec. 29, 2025) – We Work For Health commends the Trump administration for recognizing the substantial role corporate insurers and their integrated subsidiaries play in driving up costs and restricting access to care for American families. The administration's announcement of thei...

01/09/2026

12/17/2025

"The 340B program is no longer focused on serving the vulnerable — it now subsidizes hospital systems skilled at exploiting its flaws. What began as a safety net has become poorly regulated corporate welfare, with little obligation to pass savings on to patients."

View the Richmond Times-Dispatch for Tuesday, December 16, 2025

12/15/2025

"Virginia is rapidly positioning itself as a national leader in advanced pharmaceutical manufacturing, Governor Glenn Youngkin said in a recent Facebook post highlighting new investments and job growth in the sector."

Read more:

Virginia is becoming a national force in advanced pharmaceutical manufacturing, attracting $12.5 billion in new investment and creating about 3,000 new high‑paying jobs.

12/10/2025

You don't want to miss this upcoming WWFH briefing.

COMING UP: WWFH’s Dec. 11 briefing at 10 AM will explore the implications of China’s biopharma expansion for America’s healthcare and innovation ecosystem. Register here: https://docs.google.com/forms/d/e/1FAIpQLScCY7Xac7xVcq_QCgPLpfUs5USNShyarmA-2EEGxERaBi88eA/viewform

12/10/2025

Families and employers across the Commonwealth can’t wait another year for accountability. Congress must act now.
Thank you Senator Tim Kaine for continuing to support policies that help Virginians.

More than half of American adults manage multiple chronic conditions. The prevalence is enough to strain the U.S. healthcare system and challenge patient access to new treatments. To compound the issue, pharmacy benefit managers (PBMs) and others siphon nearly half of every dollar spent on brand-nam...

12/10/2025

A pharmaceutical manufacturing cluster is rising in Virginia. Here’s what that means.

Gov. Glenn Youngkin says the three big jobs announcements by pharmaceutical companies represent a “gravity pull” that can reshape the Virginia economy. Industry observers agree.

Gov. Glenn Youngkin says the three big jobs announcements by pharmaceutical companies represent a “gravity pull” that can reshape the Virginia economy. Industry observers agree.

12/08/2025

It's time to . A recent Senate hearing highlighted the urgent need for PBM reform.

In recognition of a universal desire to increase health care affordability, the Senate Finance Committee recently held a hearing titled “The Rising Cost of Health Care: Considering Meaningful Solutions for All Americans” to examine possible policy solutions. PBM reform remains the most practical...

12/05/2025

Washington Is Fighting the Wrong Battle on Health-Care Costs

Read more ⬇

Despite what politicians claim, drugs are not the main driver of growth in health-care spending — and capping their prices would only worsen the problem.

11/03/2025

Virginia can lead biotech manufacturing renaissance – if policymakers help

Merck's new $3 billion facility in Virginia marks a significant investment in U.S. drug manufacturing, driven by supportive government policies and incentives for biotech companies. f Virginians want more groundbreaking ceremonies like this, we need those policymakers to keep incentivizing research,...

11/03/2025

: "Governor Glenn Youngkin announced a landmark partnership with AstraZeneca, Eli Lilly and Company, and Merck that commits up to $120 million of private industry investment toward developing the Virginia Center for Advanced Pharmaceutical Manufacturing."

Governor Glenn Youngkin, 74th Governor of Virginia